Recombinant Human IGFBP-3R Protein
Beta LifeScience
SKU/CAT #: BLK-01982P-100UG

Human IGFBP-3R on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human IGFBP-3R Protein
Beta LifeScience
SKU/CAT #: BLK-01982P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human IGFBP-3R Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Ser39-Arg204. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | Q86XT9 |
Target Symbol | IGFBP-3R |
Synonyms | IGFBP-3R; GFBP3R; LOC124446; TMEM219 |
Species | Human |
Expression System | HEK293 |
Tag | C-hFc |
Expression Range | Ser39-Arg204 |
Mol. Weight | The protein has a predicted MW of 44.5 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Insulin-like growth factor-binding protein-3 (IGFBP-3) is a multifunctional protein known for modulating mitogenic and metabolic actions of IGFs as well as exerting a variety of biological actions not involving IGF. IGFBP-3 inhibits airway inflammation and hyper-responsiveness via an IGF-independent mechanism that involves activation of IGFBP-3R signaling and cross-talk with NF-κB signaling. The IGFBP-3/IGFBP-3R system therefore plays a pivotal role in the pathogenesis of asthma and can serve as a newly identified potential therapeutic target for this debilitating disease. |